CD8A and neoplasm: More specifically, we provide the first evidence that inclusion of the 41BB-agonist in the IRE+Combo regimen promoted unexpected responses from CD8+CD103+TCF-1+41BB+ tissue-resident memory T (TRM) cells and conventional type-1 DC (cDC1) subsets in tumor-drainage lymph nodes (TDLNs).